Mannitol versus normal saline in brain death donors and recipients of kidney allograft on delayed graft function (MAVERICK) – A double-blinded, placebo-controlled randomized clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518817-24-01

Enrollment

466

Registered

2025-04-07

Start date

2025-11-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease. Kidney transplantation.

Brief summary

Days to kidney function (see trial protocol)

Detailed description

Delayed kidney graft function (DGF), Biopsy-proven acute kidney graft rejection within 3 months, Estimated glomerular filtration rate (eGFR) at 7 days, 1 month and 3 months

Interventions

DRUGMANNITOL

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Days to kidney function (see trial protocol)	—

Secondary

Measure	Time frame
Delayed kidney graft function (DGF), Biopsy-proven acute kidney graft rejection within 3 months, Estimated glomerular filtration rate (eGFR) at 7 days, 1 month and 3 months	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026